Select Publications
Journal articles
, 2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319
, 2022, 'Clinical trial protocol for HyNOVA: Hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage iii epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)', Journal of Gynecologic Oncology, 33, http://dx.doi.org/10.3802/JGO.2022.33.E1
, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075
, 2021, 'Insights into ovarian cancer care: Report from the Anzgog ovarian cancer webinar series 2020', Journal of Gynecologic Oncology, 32, http://dx.doi.org/10.3802/JGO.2021.32.E95
, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, 162, pp. 720 - 727, http://dx.doi.org/10.1016/j.ygyno.2021.06.028
, 2021, 'Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.LBA3
, 2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for Immunotherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255
, 2020, 'Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer', Gynecologic Oncology, 159, pp. 539 - 545, http://dx.doi.org/10.1016/j.ygyno.2020.08.032
, 2020, 'EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib plus Olaparib for Ovarian Cancer after PARP Inhibition Progression', Clinical Cancer Research, 26, pp. 4206 - 4215, http://dx.doi.org/10.1158/1078-0432.CCR-19-4121
, 2020, 'Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 157, pp. 745 - 753, http://dx.doi.org/10.1016/j.ygyno.2020.03.009
, 2020, 'Risk stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with gynecological cancers: Preliminary results from a prospective single-center study.', Journal of Clinical Oncology, 38, pp. 6062 - 6062, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6062
, 2020, 'Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer', Cancer, 126, pp. 2139 - 2145, http://dx.doi.org/10.1002/cncr.32783
, 2020, 'Biomarkers of outcome with weekly paclitaxel in platinum-resistant high-grade serous or endometrioid ovarian carcinoma', Gynecologic Oncology, 159, pp. 149 - 149, http://dx.doi.org/10.1016/j.ygyno.2020.05.207
, 2020, 'Proactive inter-professional program to manage malignant bowel obstruction (MBO) in women with advanced gynecological cancer: Improving quality of care, education and awareness of malignant bowel obstruction among patients and health care providers', Gynecologic Oncology, 159, pp. 55 - 56, http://dx.doi.org/10.1016/j.ygyno.2020.06.116
, 2020, 'Supported self-management as an innovative model of care for advanced gynecologic cancer patients with malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 159, pp. 314 - 315, http://dx.doi.org/10.1016/j.ygyno.2020.05.568
, 2019, 'Management of Malignant Pleural Effusions-What Is New', SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 40, pp. 323 - 339, http://dx.doi.org/10.1055/s-0039-1698285
, 2019, 'Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.', Journal of Clinical Oncology, 37, pp. 5580 - 5580, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5580
, 2019, 'Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.', Journal of Clinical Oncology, 37, pp. 5521 - 5521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5521
, 2019, 'Implementation of malignant bowel obstruction multidisciplinary case conferences (MCCs) to improve clinical decision making in malignant bowel obstruction (MBO) in gynecologic oncology.', Journal of Clinical Oncology, 37, pp. e18322 - e18322, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18322
, 2019, 'Optimizing the care of malignant bowel obstruction in patients with advanced gynecologic cancer', Journal of Oncology Practice, 15, pp. e1066 - e1075, http://dx.doi.org/10.1200/JOP.18.00793
, 2019, 'To treat or not to treat', JNCI Cancer Spectrum, 3, pp. pkz023, http://dx.doi.org/10.1093/jncics/pkz023
, 2018, 'Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial', The Lancet Respiratory Medicine, 6, pp. 671 - 680, http://dx.doi.org/10.1016/S2213-2600(18)30288-1
, 2018, 'Prospective assessment of tumor biopsies as part of clinical trials: Patients’ (pts) perspectives.', Journal of Clinical Oncology, 36, pp. 2539 - 2539, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.2539
, 2018, 'Toxicity profile of patients with gynecological cancers (Gyne) enrolled in phase I trials.', Journal of Clinical Oncology, 36, pp. 5572 - 5572, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.5572
, 2018, 'Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective', Obstetrics and Gynecology International, 2018, pp. 1867238, http://dx.doi.org/10.1155/2018/1867238
, 2017, 'Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial', JAMA Journal of the American Medical Association, 318, pp. 1903 - 1912, http://dx.doi.org/10.1001/jama.2017.17426
, 2017, 'Novel malignant bowel obstruction (MBO) management program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2017.35.31_suppl.158
, 2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x
, 2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004
, 2017, 'Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia', Internal Medicine Journal, 47, pp. 888 - 893, http://dx.doi.org/10.1111/imj.13482
, 2017, 'Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. e18024 - e18024, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18024
, 2017, 'Thoracic ultrasound recognition of competence: A position paper of the Thoracic Society of Australia and New Zealand', Respirology, 22, pp. 405 - 408, http://dx.doi.org/10.1111/resp.12977
, 2017, 'Treatment strategies for endometrial cancer: Current practice and perspective', Current Opinion in Obstetrics and Gynecology, 29, pp. 47 - 58, http://dx.doi.org/10.1097/GCO.0000000000000338
, 2016, 'Study protocol for a randomised controlled trial of invasive versus conservative management of primary spontaneous pneumothorax', BMJ Open, 6, pp. e011826, http://dx.doi.org/10.1136/BMJOPEN-2016-011826
, 2015, 'An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer', Expert Opinion on Investigational Drugs, 24, pp. 1307 - 1320, http://dx.doi.org/10.1517/13543784.2015.1070483
, 2015, 'Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma', Molecular Cancer Research, 13, pp. 1106 - 1118, http://dx.doi.org/10.1158/1541-7786.MCR-14-0442
, 2014, 'Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis', BMJ OPEN, 4, http://dx.doi.org/10.1136/bmjopen-2014-006757
, 2013, 'Clinical Outcomes of Indwelling Pleural Catheter-Related Pleural Infections An International Multicenter Study', CHEST, 144, pp. 1597 - 1602, http://dx.doi.org/10.1378/chest.12-3103
, 2008, 'School-aged children: A reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom', Journal of Infectious Diseases, 197, pp. 1275 - 1281, http://dx.doi.org/10.1086/586716
, 2008, 'Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody', Clinical Infectious Diseases, 46, pp. 186 - 192, http://dx.doi.org/10.1086/524668
, 2006, 'Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins', Vaccine, 24, pp. 5335 - 5340, http://dx.doi.org/10.1016/j.vaccine.2006.04.021
, 2006, 'Haemophilus influenzae type b reemergence after combination immunization', Emerging Infectious Diseases, 12, pp. 937 - 941, http://dx.doi.org/10.3201/eid1206.051451